Companies ›Healthcare ›2197.HK

2197.HK — HKEX Biotechnology & Medical Research

Clover Biopharmaceuticals Ltd

HK$2,46

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Clover Biopharmaceuticals Ltd has a fully diluted share count of 1,298,233,804 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available in the current valuation snapshot, and no industry_config preferred metrics are provided for comparison. As a result, it is not possible to assess the company's profitability or returns relative to industry benchmarks at this time. The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment or geographic breakdown is provided, making it difficult to evaluate the diversification of its revenue streams. Growth trajectory data is limited. No revenue history or outlook numeric deltas are available to assess the company's growth potential in the current or next fiscal year. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The d

Business. Clover Biopharmaceuticals Ltd (2197.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments and geographic presence are not provided in the available data. The company is headquartered in Hong Kong, consistent with its primary listing location.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 2197.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 2197.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Clover Biopharmaceuticals Ltd (2197.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments and geographic presence are not provided in the available data. The company is headquartered in Hong Kong, consistent with its primary listing location.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

Profitability and return metrics are not available in the current valuation snapshot, and no industry_config preferred metrics are provided for comparison. As a result, it is not possible to assess the company's profitability or returns relative to industry benchmarks at this time.

The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment or geographic breakdown is provided, making it difficult to evaluate the diversification of its revenue streams.

Growth trajectory data is limited. No revenue history or outlook numeric deltas are available to assess the company's growth potential in the current or next fiscal year.

Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The dilution potential is currently low, as there is no difference between basic and diluted shares outstanding.

Recent events, such as filings or transcripts, are not disclosed in the available data. No specific recent developments or disclosures are available to inform the company's current strategic or operational direction.

Key takeaways

Clover Biopharmaceuticals Ltd operates in the biotechnology and medical research industry, with a focus on innovative biopharmaceutical products.
The company has no dilution risk from stock options or convertible instruments, as basic and diluted shares are equal.
Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
No profitability or return metrics are available for comparison with industry benchmarks.
Revenue concentration and geographic exposure are not disclosed, limiting visibility into the company's diversification.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2024-03-27

FY 2024 · Full-year highlights

Revenue ¥39.3M; Operating income +95,1% YoY.

Revenue¥39.3M

Operating income-¥119.8M+95,1 % YoY

Net income-¥138.5M+94,3 % YoY

Free cash flow-¥73.0M+97,1 % YoY

EPS—

Operating cash flow-¥727.9M+57,0 % YoY

Financials

Income statement

Revenue¥39.3M

Gross profit¥24.2M

Operating income-¥119.8M

Net income-¥138.5M

Margins

Gross margin61.8%

Operating margin-305.2%

Net margin-352.9%

FCF margin-185.9%

Balance sheet

Total assets¥2.10B

Total liabilities¥2.83B

Total equity-¥732.8M

Cash & equivalents¥735.9M

Long-term debt¥334.5M

Cash flow

Operating cash flow-¥727.9M

CapEx-¥9.2M

Free cash flow-¥73.0M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue ¥39.3M
▍Operating income +95,1% YoY
▍Net income +94,3% YoY
▍Free cash flow +97,1% YoY
▍Net margin -352.9%

Valuation FY

Market price

HK$2,46

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Clover Biopharmaceuticals Ltd Market data — financials · 2026-05-26

Ownership & reference

Leadership

Joshua G LiangChief Executive Officer, Executive Director
Peng LiangExecutive Chairman of the Board

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

2197.HKCanonical

HKEX · HKD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2024-03-27 03:38 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 39.3M · Net CNY -138.5M

2023-03-29 04:30 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 0.0M · Net CNY -2.45B

2022-03-29 16:27 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 0.0M · Net CNY -6.02B

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread